SCHEMBL4234552

SCHEMBL4234552

O=C(O)N[C@H]1CCN(c2nc(-c3ccccc3)no2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ FAAH O00519 1/20 0.47
▸ HSD11B1 P28845 5/20 0.47
▸ ACACB O00763 1/20 0.46
▸ MAPT P10636 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ HPGD P15428 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ HDAC3 O15379 1/20 0.45
▸ HDAC4 P56524 1/20 0.45
▸ HDAC7 Q8WUI4 1/20 0.45
▸ HDAC9 Q9UKV0 1/20 0.45
▸ HDAC5 Q9UQL6 1/20 0.45
▸ NCOR2 Q9Y618 1/20 0.45
▸ ACKR3 P25106 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4227170 0.91 SMN1; SMN2 (0.51) SMN1; SMN2MAPTLMNAPOLBMEN1
SCHEMBL14375996 0.85 CKS1B (0.56) SMN1; SMN2ACACBMAPTLMNAMEN1
SCHEMBL14349357 0.85 CKS1B (0.56) SMN1; SMN2ACACBMAPTLMNAMEN1
SCHEMBL14349266 0.81 ACACB (0.43) SMN1; SMN2FAAHHSD11B1ACACBMAPT
SCHEMBL12490134 0.80 FAAH (0.47) SMN1; SMN2FAAHMAPTLMNAPOLB
SCHEMBL4213876 0.79 ACKR3 (0.53) HSD11B1POLBACKR3
SCHEMBL8272507 0.78 MEN1 (0.43) SMN1; SMN2ACACBMAPTLMNAPOLB
SCHEMBL8271227 0.78 HDAC4 (0.49) SMN1; SMN2MAPTLMNAMEN1KMT2A
SCHEMBL4227209 0.77 NOTUM (0.44) FAAHHSD11B1LMNARAB9A
SCHEMBL12506166 0.77 GPR119 (0.51) SMN1; SMN2FAAHHSD11B1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797094-A4 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2009-06-03 — — EP disclosed
US-20070293515-A1 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists MERCK SHARP & DOHME CORP. 2007-12-20 — — US disclosed
EP-1797094-A2 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS Merck & Co. Inc. (US) 2007-06-20 — — EP disclosed
WO-2006017409-A2 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2006-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293515-A1 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists GRIN2B, GRIN2A, GRIN1 SMN1; SMN2 1128/4885FAAH 1132/4885HSD11B1 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback